Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/progestogens

Progestogens and Adverse Health Outcomes

Child being examined by medical professional and child playing with toys

Topic Overview

Status: Evaluation completed

Background Information

Progesterone produced by the body is an important hormone for maintenance of pregnancy and other reproductive functions. Progestogenic drugs, known as progestogens, are a class of drugs that produce effects similar to the natural progesterone in the body; they include both bioidentical progesterone made from plants and synthetic forms. Progestogens are given to reproductive age women for a variety of reasons, including contraception, treatment of infertility, or treatment or prevention of miscarriage and preterm birth. Children born with a condition known as congenital adrenal hyperplasia, which includes ambiguous genitalia at birth, early puberty, infertility, and altered sex-specific behaviors, show an imbalance of progesterone with other hormones. Some case reports and case series have reported adverse reproductive outcomes (e.g., masculinization of female infants) in pregnant women treated with synthetic progestogens during the first trimester, and similar effects on reproductive development have also been observed in laboratory animal studies following in utero exposure to certain synthetic progestogens.

NTP developed a scoping review and evidence map of published scientific literature. The current body of evidence was not sufficient to recommend an evaluation of the potential health effects of prenatal exposure to progestogens due to differences in the health outcomes evaluated or inconsistencies in the results. Researchers can explore the health effects data related to prenatal exposure to progestogens using the interactive evidence maps. The scoping review also includes a summary of the reported conclusions in the literature for congenital malformations and neurological development.

Documents

Date Document
Sep 26, 2018 NTP Protocol
Jul 31, 2020 NTP Protocol - Revised
Sep 25, 2020 NTP Research Report (Abstract)
Preferred Citation: National Toxicology Program (NTP). 2020. NTP research report on the scoping review of prenatal exposure to progestogens and adverse health outcomes. Research Triangle Park, NC: National Toxicology Program. Research Report 17.

Note on Accessibility: Persons with disabilities or using assistive technology may find some documents are not fully accessible. For assistance, email us or use our contact form and identify the documents/pages for which access is required. We will assist you in accessing the content of these files. NIEHS has helpful information on accessibility.